undefined undefined
NaN.000
NaN.00%
ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose levels Ionis plans to move ION582 ...
05-16 19:00
BOCA RATON, Fla., May 13, 2024 /PRNewswire/ -- In response to the soaring deman...
05-13 20:38
摩根大通证券公司:维持Halozyme Therapeutics(HALO.US)评级,由优于大市调整至优于大市评级, 目标价由72.00美元调整至71.00美...
05-09 02:01
SAN DIEGO, May 8, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Nicole LaBrosse, Chief Financial Officer, is scheduled to present and host...
05-08 20:30
Goldman Sachs analyst Corinne Johnson maintained a Hold rating on Halozyme (HAL...
05-08 10:35
Halozyme Therapeutics shares are trading higher following mixed Q1 results.
05-08 04:30
Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.69 by 14.49 percent. The company reported quarterly sales of $195.879 million which
05-08 04:24
登录新浪财经APP 搜索【信披】查看更多考评等级 重要提示 1.国联智选先锋股票型证券投资基金(以下简称“本基金”)募集的准予注册文...
05-08 00:00
Halozyme Therapeutics (NASDAQ:HALO) has been analyzed by 7 analysts in the last...
05-07 22:00
WAINUATM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission Positive Phase 3 donidalorsen data fo...
05-07 19:00